NASDAQ:IONS - Ionis Pharmaceuticals Stock Price, Price Target & More Sign in or create an account to add this stock to your watchlist. Get Started $44.27 -0.97 (-2.14 %) (As of 07/17/2018 08:26 AM ET)Previous Close$45.24Today's Range$43.93 - $45.3152-Week Range$39.07 - $65.51Volume581,276 shsAverage Volume987,159 shsMarket Capitalization$5.68 billionP/E Ratio553.38Dividend YieldN/ABeta2.63 Company ProfileFinancialsAnalyst RatingsEarnings HistoryInsider TradesHeadlinesOptions ChainSEC FilingsSocial MediaChart Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Ionis Pharmaceuticals, Inc. discovers and develops RNA-targeted therapeutics. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; and Kynamro an oligonucleotide inhibitor for use in patients with homozygous familial hypercholesterolemia to reduce low density lipoprotein-cholesterol, apolipoprotein B, total cholesterol, and non-high density lipoprotein. It is also developing inotersen, an antisense drug Ionis to treat patients with hereditary transthyretin amyloidosis; and volanesorsen, an antisense drug for the treatment of familial chylomicronemia syndrome and familial partial lipodystrophy. In addition, the company is developing drugs for various indications, such as cardiometabolic diseases caused by lipid disorders; cardiovascular disease, clotting disorders, and Alzheimer's and Parkinson's diseases; and acromegaly, amyotrophic lateral sclerosis, beta-thalassemia, and Huntington's disease. Ionis Pharmaceuticals, Inc. has a collaboration agreement with AstraZeneca to discover and develop antisense therapies for treating cardiovascular and metabolic diseases, and cancer; and Biogen Inc. to develop and commercialize therapies for neurological disorders, SMA, and neurodegenerative diseases. The company was formerly known as Isis Pharmaceuticals, Inc. and changed its name to Ionis Pharmaceuticals, Inc. in December 2015. Ionis Pharmaceuticals, Inc. was founded in 1989 and is headquartered in Carlsbad, California. Receive IONS News and Ratings via Email Sign-up to receive the latest news and ratings for IONS and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryBiotechnology SectorMedical SymbolNASDAQ:IONS CUSIP46433010 Webwww.ionispharma.com Phone760-931-9200 Debt Debt-to-Equity Ratio1.59 Current Ratio5.38 Quick Ratio5.33 Price-To-Earnings Trailing P/E Ratio553.38 Forward P/E Ratio-1,106.75 P/E GrowthN/A Sales & Book Value Annual Sales$507.67 million Price / Sales10.95 Cash Flow$0.3554 per share Price / Cash124.58 Book Value$3.36 per share Price / Book13.18 Profitability EPS (Most Recent Fiscal Year)$0.08 Net Income$-5,960,000.00 Net Margins-2.00% Return on Equity-3.06% Return on Assets-0.88% Miscellaneous Employees547 Outstanding Shares125,520,000Market Cap$5,678.52 Ionis Pharmaceuticals (NASDAQ:IONS) Frequently Asked Questions What is Ionis Pharmaceuticals' stock symbol? Ionis Pharmaceuticals trades on the NASDAQ under the ticker symbol "IONS." How were Ionis Pharmaceuticals' earnings last quarter? Ionis Pharmaceuticals Inc (NASDAQ:IONS) issued its earnings results on Friday, May, 4th. The company reported ($0.01) earnings per share for the quarter, beating the consensus estimate of ($0.11) by $0.10. The business had revenue of $144.40 million for the quarter, compared to analyst estimates of $144.01 million. Ionis Pharmaceuticals had a negative net margin of 2.00% and a negative return on equity of 3.06%. The firm's revenue was up 24.7% on a year-over-year basis. During the same period in the previous year, the business earned $0.03 EPS. View Ionis Pharmaceuticals' Earnings History. What price target have analysts set for IONS? 11 brokers have issued 1-year price targets for Ionis Pharmaceuticals' stock. Their forecasts range from $18.00 to $75.00. On average, they expect Ionis Pharmaceuticals' share price to reach $53.00 in the next twelve months. This suggests a possible upside of 19.7% from the stock's current price. View Analyst Ratings for Ionis Pharmaceuticals. What is the consensus analysts' recommendation for Ionis Pharmaceuticals? 11 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Ionis Pharmaceuticals in the last year. There are currently 3 sell ratings, 4 hold ratings and 4 buy ratings for the stock, resulting in a consensus recommendation of "Hold." Who are some of Ionis Pharmaceuticals' key competitors? Some companies that are related to Ionis Pharmaceuticals include Mylan (MYL), BioMarin Pharmaceutical (BMRN), UCB (UCBJF), GRIFOLS S A/S (GRFS), Merck KGaA (MKGAF), Ono Pharmaceutical (OPHLF), Alnylam Pharmaceuticals (ALNY), Jazz Pharmaceuticals (JAZZ), Perrigo (PRGO), Genmab A/S (GNMSF), Sarepta Therapeutics (SRPT), Beigene (BGNE), Nektar Therapeutics (NKTR), Valeant Pharmaceuticals (VRX) and SAGE Therapeutics (SAGE). Who are Ionis Pharmaceuticals' key executives? Ionis Pharmaceuticals' management team includes the folowing people: Dr. Stanley T. Crooke, Founder, Exec. Chairman, CEO & Pres (Age 73)Dr. Brett P. Monia, Founder, COO and Sr. VP of Antisense Drug Discovery & Translational Medicine (Age 57)Ms. Elizabeth L. Hougen, CFO & Sr. VP of Fin. (Age 56)Dr. Richard S. Geary Ph.D., Sr. VP of Devel. (Age 60)Ms. B. Lynne Parshall, Sr. Strategic Advisor & Director (Age 64) Has Ionis Pharmaceuticals been receiving favorable news coverage? News stories about IONS stock have been trending somewhat positive recently, Accern Sentiment Analysis reports. The research firm scores the sentiment of news coverage by analyzing more than 20 million news and blog sources in real time. Accern ranks coverage of companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Ionis Pharmaceuticals earned a media sentiment score of 0.21 on Accern's scale. They also assigned news headlines about the company an impact score of 46.14 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the stock's share price in the near term. Who are Ionis Pharmaceuticals' major shareholders? Ionis Pharmaceuticals' stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include Scout Investments Inc. (0.29%), Peregrine Capital Management LLC (0.26%), BLB&B Advisors LLC (0.20%), Bank of Montreal Can (0.02%), Xact Kapitalforvaltning AB (0.02%) and State of Alaska Department of Revenue (0.01%). Company insiders that own Ionis Pharmaceuticals stock include B Lynne Parshall, Brett P Monia, C Frank Bennett, Elizabeth L Hougen, Frederick T Muto, Ionis Pharmaceuticals Inc, Joseph H Wender, Joseph Klein III, Patrick R O'neil, Richard S Geary, Sarah Boyce, Spencer R Berthelsen and Stanley T Crooke. View Institutional Ownership Trends for Ionis Pharmaceuticals. Which major investors are selling Ionis Pharmaceuticals stock? IONS stock was sold by a variety of institutional investors in the last quarter, including BLB&B Advisors LLC. Company insiders that have sold Ionis Pharmaceuticals company stock in the last year include B Lynne Parshall, Brett P Monia, C Frank Bennett, Elizabeth L Hougen, Frederick T Muto, Joseph H Wender, Joseph Klein III, Patrick R O'neil, Richard S Geary, Sarah Boyce, Spencer R Berthelsen and Stanley T Crooke. View Insider Buying and Selling for Ionis Pharmaceuticals. Which major investors are buying Ionis Pharmaceuticals stock? IONS stock was bought by a variety of institutional investors in the last quarter, including Peregrine Capital Management LLC, Scout Investments Inc., State of Alaska Department of Revenue, Xact Kapitalforvaltning AB and Bank of Montreal Can. View Insider Buying and Selling for Ionis Pharmaceuticals. How do I buy shares of Ionis Pharmaceuticals? Shares of IONS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is Ionis Pharmaceuticals' stock price today? One share of IONS stock can currently be purchased for approximately $44.27. How big of a company is Ionis Pharmaceuticals? Ionis Pharmaceuticals has a market capitalization of $5.68 billion and generates $507.67 million in revenue each year. The company earns $-5,960,000.00 in net income (profit) each year or $0.08 on an earnings per share basis. Ionis Pharmaceuticals employs 547 workers across the globe. How can I contact Ionis Pharmaceuticals? Ionis Pharmaceuticals' mailing address is 2855 GAZELLE COURT, CARLSBAD CA, 92010. The company can be reached via phone at 760-931-9200. MarketBeat Community Rating for Ionis Pharmaceuticals (NASDAQ IONS)Community Ranking: 2.5 out of 5 ( )Outperform Votes: 459 (Vote Outperform)Underperform Votes: 447 (Vote Underperform)Total Votes: 906MarketBeat's community ratings are surveys of what our community members think about Ionis Pharmaceuticals and other stocks. Vote "Outperform" if you believe IONS will outperform the S&P 500 over the long term. Vote "Underperform" if you believe IONS will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 7/17/2018 by MarketBeat.com StaffFeatured Article: How do investors use RSI to grade stocks?